Evidence map›Paper›PMID 36614038›Full record

ArticleInternational journal of molecular sciences2022

Blocking Muscarinic Receptor 3 Attenuates Tumor Growth and Decreases Immunosuppressive and Cholinergic Markers in an Orthotopic Mouse Model of Colorectal Cancer.

Nyanbol Kuol, Majid Davidson, Jimsheena Karakkat, Rhiannon T Filippone, Margaret Veale, Rodney Luwor, Sarah Fraser, Vasso Apostolopoulos, Kulmira Nurgali

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Anisodus tanguticus in Cancer Research: A Review of Traditional Use, Phytochemistry, Extraction Methods, and Preclinical Antitumor Evidence.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Nyanbol KuolInstitute for Health and Sport, Victoria University, Melbourne 3011, Australia.ORCID 0000-0002-8269-3757
Majid DavidsonInstitute for Health and Sport, Victoria University, Melbourne 3011, Australia.ORCID 0000-0002-3241-6444
Jimsheena KarakkatInstitute for Health and Sport, Victoria University, Melbourne 3011, Australia.
Rhiannon T FilipponeInstitute for Health and Sport, Victoria University, Melbourne 3011, Australia.
Margaret VealeLa Trobe Institute of Molecule Science, La Trobe University, Melbourne 3086, Australia.
Rodney LuworRoyal Melbourne Hospital, University of Melbourne, Melbourne 3010, Australia.ORCID 0000-0002-3020-4245
Sarah FraserInstitute for Health and Sport, Victoria University, Melbourne 3011, Australia.
Vasso ApostolopoulosInstitute for Health and Sport, Victoria University, Melbourne 3011, Australia.ORCID 0000-0001-6788-2771
Kulmira NurgaliInstitute for Health and Sport, Victoria University, Melbourne 3011, Australia.ORCID 0000-0002-2597-6929
Victoria University · AUAustralian Institute for Musculoskeletal Science · AULa Trobe University · AUThe Royal Melbourne Hospital · AUThe University of Melbourne · AUUniversity of Nevada, Reno · US

Funding

Graeme and Angelina Wise Foundation Philanthropic grant (V.A.)Thelma and Paul Constantinou Foundation Philanthropic grantThelma and Paul Constantinou Foundation Philanthropic grant (V.A.)
6 · The paper itself

Abstract

Tumor cells have evolved to express immunosuppressive molecules allowing their evasion from the host's immune system. These molecules include programmed death ligands 1 and 2 (PD-L1 and PD-L2). Cancer cells can also produce acetylcholine (ACh), which plays a role in tumor development. Moreover, tumor innervation can stimulate vascularization leading to tumor growth and metastasis. The effects of atropine and muscarinic receptor 3 (M3R) blocker, 1,1-dimethyl-4-diphenylacetoxypiperidinium iodide (4-DAMP), on cancer growth and spread were evaluated in vitro using murine colon cancer cell line, CT-26, and in vivo in an orthotopic mouse model of colorectal cancer. In the in vitro model, atropine and 4-DAMP significantly inhibited CT-26 cell proliferation in a dose dependent manner and induced apoptosis. Atropine attenuated immunosuppressive markers and M3R via inhibition of EGFR/AKT/ERK signaling pathways. However, 4-DAMP showed no effect on the expression of PD-L1, PD-L2, and choline acetyltransferase (ChAT) on CT-26 cells but attenuated M3R by suppressing the phosphorylation of AKT and ERK. Blocking of M3R in vivo decreased tumor growth and expression of immunosuppressive, cholinergic, and angiogenic markers through inhibition of AKT and ERK, leading to an improved immune response against cancer. The expression of immunosuppressive and cholinergic markers may hold potential in determining prognosis and treatment regimens for colorectal cancer patients. This study's results demonstrate that blocking M3R has pronounced antitumor effects via several mechanisms, including inhibition of immunosuppressive molecules, enhancement of antitumor immune response, and suppression of tumor angiogenesis via suppression of the AKT/ERK signaling pathway. These findings suggest a crosstalk between the cholinergic and immune systems during cancer development. In addition, the cholinergic system influences cancer evasion from the host's immunity.

Indexed as

Colorectal NeoplasmsLung NeoplasmsAnimalsAtropineB7-H1 AntigenCholinergic AgentsMiceProto-Oncogene Proteins c-aktReceptor, Muscarinic M3Receptors, MuscarinicAtropineB7-H1 AntigenCholinergic AgentsProto-Oncogene Proteins c-aktReceptor, Muscarinic M3Receptors, Muscariniccholine acetyltransferasecolorectal cancerimmunosuppressivemuscarinic receptor 3programmed death ligands 1 and 2α7 nicotinic acetylcholine receptor

Identifiers

PMID36614038
PMCPMC9820315
OpenAlexW4313360794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.